Healio Research. Healio/OSN Eyecelerator survey on practice trends. Presented at: Eyecelerator; May 4, 2023; San Diego.
Kilman is the program director for Eyecelerator. Healio Research is a department within Healio, a Wyanoke Group company.
SAN DIEGO — While cuts to reimbursement, inflation and the threat of recession were seen by survey respondents as the biggest practice challenges, one respondent wrote “all these will affect the ability to see more patients and grow.”
The “all” survey respondents were asked to identify were factors that will have the greatest impact on practice growth in 2023. These factors were cuts to reimbursement (35%), economic recession/rate of inflation (27%), hiring/staffing shortages (22%), competition of other practices (12%) and office/ASC space constraints (2%).
Healio/OSN commissioned Healio Research to conduct a survey on ophthalmologists’ sentiment toward innovation in key product areas. Healio Research disseminated a survey of 10 questions to U.S. ophthalmologists and residents. The questions were created in partnership with Eyecelerator, and the survey received 256 responses.
When respondents were asked to look prognostically at what procedures would most likely increase practice revenue in the next 5 years, 40% chose premium channel cataract surgery, followed by bilateral simultaneous in-office cataract surgery (25%), management by private equity consolidator (16%) and MIGS (13%).
When asked what post-FDA approval factors inhibit their adoption of ophthalmic technology, one-third of survey respondents indicated cost was the biggest factor, followed by the learning curve (24%) and reimbursement (21%).
Respondents were asked to project what drug categories would see the greatest growth in 2023. Not surprisingly, dry eye, glaucoma drug delivery, glaucoma topical therapeutics and intracameral medications for cataract led the pack.
In September, Healio/OSN published survey data on technology trends.
Healio Research conducted a survey in February on health care provider adoption of digital therapeutics. The results were published on Healio’s sister company’s site.